Cited 1 times in
Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유성환 | - |
dc.contributor.author | 이현웅 | - |
dc.contributor.author | 김소라 | - |
dc.date.accessioned | 2022-05-09T17:08:05Z | - |
dc.date.available | 2022-05-09T17:08:05Z | - |
dc.date.issued | 2022-03 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188396 | - |
dc.description.abstract | Background: Hepatocellular carcinoma (HCC) rarely develops in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR). We assessed the incidence of HCC in CHC patients with hemophilia after treatment with pegylated interferon plus ribavirin (PegIFN/RBV) and direct-acting antivirals (DAAs). Methods: Patients (n = 202) were enrolled between March 2007 and July 2019. A total of 139 patients were treated with PegIFN/RBV (genotype 1, n = 98; genotype 2, n = 41). Sixty-three patients were treated with DAAs (genotype 1, n = 44; genotype 2, n = 19). The cumulative incidence rates of HCC were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: For genotype 1, SVR was achieved in 78.6% (77/98) and 90.9% (40/44) of patients in the PegIFN/RBV and DAAs groups, respectively. For genotype 2, SVR was achieved in 95.1% (39/41) and 94.7% (18/19) of patients in the PegIFN/RBV and DAAs groups, respectively. Six HCC cases were identified. The cumulative incidence of HCC was 4.1% at 14 years in PegIFN/RBV and 1.7% at 5 years in DAAs. The 14-year cumulative incidence of HCC was 1.9% in the SVR group and 21.7% in the no-SVR group in the PegIFN/RBV group (p < 0.001). Conclusions: Treatment with PegIFN/RBV led to stable SVR and a low incidence of HCC. Although the follow-up period was short, DAAs led to more stable SVR than PegIFN/RBV and a low incidence of HCC in CHC patients with hemophilia. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | MDPI AG | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Low Incidence of Hepatocellular Carcinoma after Antiviral Therapy in Patients with Chronic Hepatitis C and Hemophilia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | In Jung Kim | - |
dc.contributor.googleauthor | Sung Hwan Yoo | - |
dc.contributor.googleauthor | Sora Kim | - |
dc.contributor.googleauthor | Young Youn Cho | - |
dc.contributor.googleauthor | Ki Young Yoo | - |
dc.contributor.googleauthor | Hyung Joon Kim | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.identifier.doi | 10.3390/jcm11051451 | - |
dc.contributor.localId | A05883 | - |
dc.contributor.localId | A03292 | - |
dc.relation.journalcode | J03556 | - |
dc.identifier.eissn | 2077-0383 | - |
dc.identifier.pmid | 35268541 | - |
dc.subject.keyword | chronic hepatitis C | - |
dc.subject.keyword | hemophilia | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.contributor.alternativeName | Yoo, Sung Hwan | - |
dc.contributor.affiliatedAuthor | 유성환 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1451 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, Vol.11(5) : 1451, 2022-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.